News Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
31.71 ^USD	+1.44%		+7.09%	+38.29%

May. 07	Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 03	Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Protagonist Therapeutics: Q1 Earnings Snapshot	May. 07	AQ
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	Apr. 03	MT
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	Mar. 27	AQ
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	Mar. 26	CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	Mar. 18	CI
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	Mar. 11	MT
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	Mar. 11	CI
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	Mar. 04	MT
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	Mar. 04	MT
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	Feb. 28	MT
Protagonist Therapeutics: Q4 Earnings Snapshot	Feb. 27	AQ
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	Jan. 31	DJ
Transcript : Protagonist Therapeutics, Inc. - Special Call	Jan. 31
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	Jan. 31	CI
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	Jan. 30	AQ
Transcript : Protagonist Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:45 AM	Jan. 09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Summary

Filters